Neuropeptide W (NPW) is produced in neurons located in hypothalamus and brain stem and its receptors are present in the hypothalamus, in particular in the paraventricular nucleus (PVN). Intracerebroventricular (i.c.v.) administration of NPW activated, in a dose related fashion, the hypothalamo-pituitary-adrenal (HPA) axis as determined by plasma corticosterone levels in conscious rats but, at those same doses, did not stimulate the release of oxytocin or vasopressin into the peripheral circulation or alter blood pressure or heart rate. The ability of i.c.v. administered NPW to stimulate the HPA axis in conscious male rats was blocked by intravenous pretreatment with a corticotropin releasing hormone (CRH) antagonist. This suggested an action of NPW in the parvocellular division of the PVN. Indeed, in hypothalamic slice preparations (whole cell patch recording) bath application of NPW depolarized, and increased the spike frequency of the majority of electrophysiologically identified putative neuroendocrine PVN neurons. Effects on membrane potential were maintained in the presence of tetrodotoxin suggesting them to be direct postsynaptic actions on these neuroendocrine cells. Our data suggest that endogenous NPW, produced in brain, may play a physiologically relevant role in the neuroendocrine response to stress.
Introduction
Two novel gene products encoding opioid-and somatostatin-like receptors were identified in hypothalamic areas known to be important in the neuroendocrine regulation of anterior pituitary hormone secretion (9) . Using Northern blot analysis O'Dowd and colleagues demonstrated the expression of these genes in human brain and reported, by in situ hybridization histochemistry, the presence of gene transcripts in discrete hypothalamic areas of the mouse brain (9) . An even wider distribution of the genes encoding one of these receptor-like proteins, termed GPR7, than had been observed in mouse and human brain, was subsequently identified in rat brain (6) . In particular, gene transcripts for these receptors were observed in the paraventricular (PVN) and supraoptic (SON) nuclei, the arcuate nucleus (ARC), and in the ventromedial (VMH) and dorsomedial (DMH) nuclei, as well as in the suprachiasmatic nuclei (SCN) in the rat.
The endogenous ligands for these orphan receptors remained unidentified until 2002, when the Takeda group of Fujino and colleagues identified and sequenced two novel peptides, neuropeptide W (14) and neuropeptide B (4) . These peptides, although homologous, appear to be products of unique genes, which are expressed in separate populations of neurons (17) . We recently have reported (1) that neuropeptide W acts in brain to stimulate prolactin (PRL) release and activate the hypothalamo-pituitary-adrenal (HPA) axis, while inhibiting growth hormone (GH) secretion. No significant effects of neuropeptide W on hormone release from cultured, anterior pituitary cells were observed, leading us to suggest that endogenously produced NPW, acting via GPR7, plays an important role in the hypothalamic organization of the endocrine response to stress (1) .
We hypothesized that neuropeptide W (NPW) activates the hypothalamopituitary-adrenal (HPA) axis by an action in the parvocellular paraventricular nucleus of the hypothalamus (PVN) and that this action of NPW is mediated by release of corticotropin releasing hormone (CRH) into the hypophyseal portal circulation. Results presented here demonstrate that the ability of centrally administered NPW to elevate circulating corticosterone levels in conscious, unrestrained rats can be blocked by compromise of CRH action in the anterior pituitary gland. Furthermore, NPW exerts depolarizing effects on neurons in the parvocellular division of the hypothalamic PVN, suggesting a direct action of NPW on CRH-producing cells in the nucleus.
Method and Materials
In vivo experiments: All procedures were approved by the Saint Louis University Animal ml/100 gram body weight, intraperitoneal injection) rats were placed in a stereotaxic device and a 23 gauge, stainless steel cannula (17 mm) implanted into the right lateral cerebroventricle as previously described (12) . Minimally five days later, after the animals had returned to preimplantation body weights, an indwelling jugular vein cannula was implanted as previously described (5) under isoflurane-induced anesthesia (IsoSol, Vedco Inc.). The jugular cannula was exteriorized at the back of the neck and sealed with heparinized saline (200 units/ml 0.9% NaCl). On the following day, an extension tubing (PE-50) was attached to the jugular cannula to facilitate blood sampling and rats left undisturbed for 60 minutes. Then, an initial blood sample was withdrawn from the jugular vein without disturbing the animal. All blood samples (0.3-0.4 ml) were removed from conscious, unrestrained rats into heparinized syringes and replaced with an equal volume of 0.9% NaCl (37 C). Blood samples were stored on ice before plasma was separated (10,000 X g, 5 min) and stored at -20 C until hormone assay (corticosterone) conducted. Immediately following the removal of the initial (0 time) blood sample, rats were pretreated (13) with saline vehicle or vehicle containing 0.2 mg CRH antagonist (alpha-helical CRF 9-41 , Phoenix Pharmaceuticals, Belmont, CA, intravenous). Fifteen minutes later a second blood sample was collected and then all animals received a central (i.c.v.) injection of 1.0 nmole NPW-23 (Phoenix Pharmaceuticals), in 2 microliters saline.
Blood samples were collected as before 30, 45 and 60 minutes after the i.c.v. injections.
In another group of conscious male rats, saline vehicle (2 microliters) or vehicle containing 1.0 or 3.0 nmole NPW was injected i.c.v. (as above) , and rats sacrificed by decapitation 15 minutes later. Trunk bloods were collected into heparinized tubes and plasma collected following centrifugation (4 C, 10 min, 600Xg). Plasma oxytocin and vasopressin contents were determined by RIA (10, 11) .
In a separate group of rats (n=8) bearing lateral cerebroventricular cannulas, the left carotid artery was cannulated as previously described (12) . On the following day, rats were moved to a quiet room and the carotid cannula connected to a pressure transducer (Digi-Med BPA, Micro-Med, Louisville, KY). Blood pressure and heart rate were monitored for a 1 hr stabilization period prior to i.c.v. injection of 2 µl saline vehicle or vehicle containing 1.0 or 3.0 nmole NPW. Blood pressure (systolic, diastolic and mean arterial pressures) and heart rates were monitored at 10 sec intervals for 30 min after peptide or vehicle administration. Treatments were administered in random order, all rats receiving saline and both doses of NPW. At the end of all testing periods, 50 pmole angiotensin II was injected i.c.v. to verify cannula patency (dipsogenic response and increased mean arterial pressure).
Radioimmunoassays: Plasma corticosterone levels were determined according to the instructions of the commercial RIA kit (rat/mouse corticosterone, ICN Biomedicals, Inc., Costa Mesa, CA) as previously described (1) . The minimum detectable hormone level was 25 ng/ml, and the inter-assay and intra-assay coefficients of variability were less than 10%. Plasma vasopressin (AVP) and oxytocin (OT) levels were determined by radioimmunossays uniquely developed in our laboratory (10, 11) . The lower limits of sensitivity in those assays were defined as minimally 95% of total binding for AVP (0.125 pg/ml plasma) and OT (2 pg/ml plasma). The intra-and inter-assay coefficients of variabilities for these assays were less than 7%.
Statistical analyses: For the in vivo hormone experiments, data were analyzed by ANOVA (with Scheffe's multiple comparison post-hoc testing) both within treatment groups across time and across treatment groups at any sampling time point. Blood pressure and heart rate responses were analyzed similarly at 1 min intervals. Significance was assigned to results that occurred with less than 5% probability.
Slice preparation: Experiments were performed using hypothalamic slices prepared as previously described (7) . Male Sprague-Dawley rats (150-250 g, Charles River, Quebec, Canada) were decapitated, and the brain quickly removed from the skull and immersed in cold (1-4 °C) artificial cerebrospinal fluid (aCSF). The hypothalamus was blocked and 300 µm slices including the PVN were cut using a vibratome. Slices were incubated in oxygenated aCSF (95 % O 2 -5 % CO 2 ) for at least 60 min at room temperature. Fifteen minutes prior to recording, the slice was transferred into an interface-type recording chamber and continuously perfused with oxygenated aCSF (see below for solution composition) at a rate of 1 ml/min. All techniques were carried out in accordance with the guidelines of the Canadian Council for Animal Care and were approved by Queen's University Animal Care Committee.
Electrophysiology: Whole-cell patch recordings were obtained from PVN neurons using blind patch techniques as described previously (7) . Signals were processed with an Axoclamp-2B amplifier and a Ag-AgCl electrode connected to the bath solution via a KCl-agar bridge which served as reference. A 3-8 mV (measured at end of each recording) liquid junction potential correction was applied to all data presented. Drugs were applied by switching perfusion from aCSF to a solution containing the desired drug.
All signals were digitized (5KHz) using the CED 1401 plus interface (CED, Cambridge, UK) and stored on computer for off-line analysis. Data were collected using Spike2 Cell Identification: Cells were functionally characterized in accordance with previous studies demonstrating that specific electrophysiological fingerprints are associated with magnocellular (transient potassium currents (18)), preautonomic (low threshold calcium currents (15)), or neuroendocrine neurons (NE) (neither of the above (8) see Figure 2D ).
In view of our specific focus in these studies on effects of NPW on CRH neurons our recordings were obtained from neurons in the medial parvocellular subdivision (macroscopically identified) with the purpose of primarily recording from neuroendocrine parvocellular neurons.
Analysis: All neurons included in this analysis maintained action potentials of at least 60mV in magnitude throughout the recording period and maintained a stable baseline membrane potential for at least 100s prior to application of NPW. Following peptide application, responses were characterized as: depolarization -> 3mV increase in membrane potential followed by a return to baseline, hyperpolarization ->3mV decrease in membrane potential, or no response -< 3mV change in membrane potential. Changes were evaluated by measuring the peak membrane potential change maintained for a minimum of 10 s (this excludes transient changes such as action potentials/postsynaptic potentials) following peptide application.
Results
We verified our earlier report (1) of the ability of NPW to act in brain to elevate plasma corticosterone levels ( Figure 1 ). We pretreated animals with vehicle or the CRH antagonist (i.v. to compromise CRH function in the anterior pituitary gland) and then administered the minimum effective dose of the GPR7 ligand i.c.v. to determine if the stimulation of the HPA axis was due to increased release of CRH into the portal vessels.
Saline vehicle pretreatment did not significantly alter plasma corticosterone levels prior to NPW administration (0 minute levels versus 15 minutes levels, p=0.99). Furthermore, no significant differences in plasma corticosterone levels were observed between the two It is possible that the residual corticosterone elevation in the CRH antagonist (i.v.) pretreated, NPW (i.c.v.) administered animals was due to an effect of the peptide on AVP or OT secretion since both of these peptides, under certain conditions, can act in the pituitary gland as corticotropin releasing factors (19) . However, doses of NPW (1.0 and 3.0 nmole i.c.v.) that significantly elevated plasma corticosterone levels failed to significantly alter plasma levels of vasopressin or oxytocin in conscious male rats (Table   1 ).
Mean arterial pressures and heart rates were not significantly different between treatment groups prior to i.c.v. injections. No significant changes in MAP and HR were observed following saline vehicle injection i.c.v. (within group ANOVA). Similarly, neither dose of NPW significantly altered MAP or HR in these animals, when values were compared within group or between groups compared to control. However, MAP did significantly rise in these animals following i.c.v. administration of 50 picomoles angiotensin II (Table 2 ). Heart rates declined following A II administration reflecting in all likelihood reflex bradycardia in response to the pressor effect of the peptide, although significance was not obtained.
Results from the neuroendocrine protocol suggested that NPW exerts its effects on the HPA axis by an action in brain and in particular in the parvocellular PVN, site of the CRH-producing neurons that project to median eminence. We then sought to investigate that possibility by examining the effects of bath application of NPW on the activity of single electrophysiologically identified neurons in the parvocellular region of PVN in the hypothalamic slice preparation using patch clamp recording techniques.
Whole-cell current clamp recordings were obtained from 28 electrophysiologically characterized NE PVN neurons (8, 15, 18) . These NE neurons were tested for the effects small spontaneous changes in membrane potential observed during vehicle perfusion (unpaired t-test, p<0.001)( Figure 2E) . The remaining NE neurons tested either 13 showed no response (-0.8 ± 0.9mV, n=5) or hyperpolarizations (-9.9 ± 1.7mV, n=6) in response to NPW. At the higher concentrations of NPW complete return to baseline membrane potential often did not occur within the 30 minute post application recording period, while recovery was normally observed within 15 minutes of return to aCSF following lower concentrations of NPW (100pM, 1nM) as illustrated in Figure 2A and In addition to the depolarizing effect of NPW on NE neurons, statistically significant increases in spike frequency were also observed with mean spike frequency changing from control values of 0.054 ± 0.016 Hz to 0.287 ± 0.025 Hz during NPW treatment, followed by a return to baseline (0.047 ± 0.007 Hz) (ANOVA followed by Neuman Keuls, p<0.001 compared to control and recovery) as illustrated in Figure 2F . In an additional 5 neuroendocrine cells depolarizing effects were still observed in response to NPW during bath perfusion with TTX (1mM), with 3 of 5 NE cells tested (similar proportion of responsive neurons) showing a mean depolarization of 13.7 ± 4.2mV ( Figure 2C,E) , effects that were not statistically different to those observed in response to NPW in normal aCSF (t-test, p>0.2).
Discussion
The identification of the endogenous ligands for several G-protein coupled orphan receptors allowed new insight into the hypothalamic mechanisms controlling appetite, metabolism and neuroendocrine function (3, 17) . Recently, two endogenous ligands for the orphan receptor GPR7, previously demonstrated to be in high abundance in hypothalamus (6), were identified. One, NPW appears to be produced predominantly in brain stem nuclei (17) , but immunoreactivity was also detected in parvocellular paraventricular hypothalamic nucleus and the supraoptic nucleus (2) . The presence of GPR7 mRNA in hypothalamic sites known to be important in the control of anterior pituitary function and appetite regulation suggested to us that NPW might act within those sites to regulate neuroendocrine function. Indeed, in their initial description of the identity of NPW, Shimomura and colleagues reported that single doses of centrally administered NPW stimulated feeding and prolactin secretion (14) . We have extended those findings (1) to include a description of the dose related stimulation of prolactin secretion by centrally administered NPW and demonstrated the concomitant increase in plasma corticosterone levels and the decrease in growth hormone levels in those animals.
Since no significant effects of NPW on the in vitro releases of PRL, ACTH or GH were observed in anterior pituitary cell cultures, we have hypothesized that NPW, acting within the hypothalamus, controls stress hormone secretion by increasing the release of corticotropin releasing hormone and somatostatin and decreasing the release of dopamine and GHRH into the median eminence and thus the hypophysial portal vasculature.
Our present study demonstrates that the ability of centrally administered NPW to activate the HPA axis is likely mediated via an increase of CRH release in median eminence for delivery to the corticotrophs of the anterior pituitary gland. Indeed, pretreatment of animals with a dose of CRH antagonist previously demonstrated by us to abrogate CRH actions in the pituitary gland (13) significantly attenuated the ability of exogenous NPW to activate the HPA axis. Our electrophysiological data, in addition, support the conclusion that NPW exerts these effects as a result of activation of CRH neurons in the parvocellular division of the paraventricular nucleus rather than potential actions on nerve terminals in the median eminence. Our demonstration that NPW effects are still observed when these neurons are placed in synaptic isolation by bath perfusion with TTX also supports the conclusion that such effects are in fact a result of direct actions of NPW on the post-synaptic membrane of these neurons. While we recognize that electrophysiologically identified NE neurons are not homogenous in their chemical phenotype, available evidence suggests that the majority (16) of these neurons are in fact CRH producing, supporting the conclusion that the majority of NE cells recorded in these studies are CRH producing neurons (18) . Interestingly, a small proportion of neuroendocrine-type PVN cells were hyperpolarized by NPW, observations which may correlate with the previous suggested mechanisms for NPW effects on prolactin (inhibition of dopamine neurons) (1, 14) or growth hormone (inhibition of growth hormone releasing hormone neurons) (1) secretion. It will be important for us to develop the methodology to definitively identify the peptide phenotype of the neurons in our slice preparations that respond directly to NPW and we are working toward that goal.
Selectivity of the effect of NPW is indicated by the failure of this peptide to alter the release from magnocellular PVN neurons of AVP or OT, two additional stress hormones originating in hypothalamus, that also under select circumstances can act as releasing factors to stimulate ACTH release (19) . It appears that the actions of NPW are expressed in hypothalamus and not after "leakage" into the portal vasculature, since no significant effects of the peptide on basal or releasing factor-stimulated ACTH secretion were observed in primary cell cultures (1) . Thus, the function of GPR7 in anterior pituitary (9) remains unclear.
In summary, these results support our hypothesis that endogenous NPW plays a role in the afferent signals controlling CRH release and further suggest that endogenous NPW may be a physiologically relevant messenger in the brain networks that activate the HPA axis in response to stress. Our data indicate that the depolarizing effects of NPW in vitro are direct and are not mediated via interneurons. This would suggest that NPW receptors are present on cells in parvocellular PVN and perhaps on CRH-producing neurons in the nucleus. It will be important to develop the methodologies to identify NPW-responsive neurons on the basis of chemical content. Just the same we now can suggest that the central action of NPW to activate the HPA axis is, in the end, mediated by increased activity of CRH neurons. We must now identify the conditions under which NPW is released in the PVN, and the consequences of loss of NPW function or production on stress-induced ACTH and corticosterone release. neurohypophysial peptides, and other substances on cultured corticotropic cells. 
